Pioglitazone

Caroline Day; Clifford J. Bailey

doi:10.1016/B978-008055232-3.62424-9

Pioglitazone

Caroline Day^*
, Clifford J. Bailey

^*Corresponding author for this work

Aston University

Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review

2 Citations (Scopus)

Abstract

Pioglitazone is a thiazolidinedione (TZD) antihyperglycemic agent introduced in 1999 for the treatment of type 2 (non-insulin dependent) diabetes mellitus. Another TZD, rosiglitazone, is also used in the treatment of type 2 diabetes. Troglitazone has been withdrawn from clinical use, and other TZDs, such as ciglitazone, have not proceeded into clinical use. Pioglitazone, like other TZDs, improves insulin action mainly by activation of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Peroxisome proliferator-activated receptor-gamma is most strongly expressed in adipose tissue and weakly expressed in liver and skeletal muscle, and activation of PPAR-gammain these tissues reinforces the effects of insulin. Pioglitazone may exert effects on other tissues that express PPAR-gamma ..... © 2007

Original language	English
Title of host publication	xPharm
Subtitle of host publication	the comprehensive pharmacology reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier
Number of pages	4
ISBN (Print)	978-0-08-055232-3
DOIs	https://doi.org/10.1016/B978-008055232-3.62424-9
Publication status	Published - 1 Dec 2011

Access to Document

10.1016/B978-008055232-3.62424-9

Cite this

@inbook{06a8375b30ff4d639682842533043abb,

title = "Pioglitazone",

abstract = "Pioglitazone is a thiazolidinedione (TZD) antihyperglycemic agent introduced in 1999 for the treatment of type 2 (non-insulin dependent) diabetes mellitus. Another TZD, rosiglitazone, is also used in the treatment of type 2 diabetes. Troglitazone has been withdrawn from clinical use, and other TZDs, such as ciglitazone, have not proceeded into clinical use. Pioglitazone, like other TZDs, improves insulin action mainly by activation of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Peroxisome proliferator-activated receptor-gamma is most strongly expressed in adipose tissue and weakly expressed in liver and skeletal muscle, and activation of PPAR-gammain these tissues reinforces the effects of insulin. Pioglitazone may exert effects on other tissues that express PPAR-gamma ..... {\textcopyright} 2007",

author = "Caroline Day and Bailey, \{Clifford J.\}",

year = "2011",

month = dec,

day = "1",

doi = "10.1016/B978-008055232-3.62424-9",

language = "English",

isbn = "978-0-08-055232-3",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Pioglitazone

AU - Day, Caroline

AU - Bailey, Clifford J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Pioglitazone is a thiazolidinedione (TZD) antihyperglycemic agent introduced in 1999 for the treatment of type 2 (non-insulin dependent) diabetes mellitus. Another TZD, rosiglitazone, is also used in the treatment of type 2 diabetes. Troglitazone has been withdrawn from clinical use, and other TZDs, such as ciglitazone, have not proceeded into clinical use. Pioglitazone, like other TZDs, improves insulin action mainly by activation of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Peroxisome proliferator-activated receptor-gamma is most strongly expressed in adipose tissue and weakly expressed in liver and skeletal muscle, and activation of PPAR-gammain these tissues reinforces the effects of insulin. Pioglitazone may exert effects on other tissues that express PPAR-gamma ..... © 2007

AB - Pioglitazone is a thiazolidinedione (TZD) antihyperglycemic agent introduced in 1999 for the treatment of type 2 (non-insulin dependent) diabetes mellitus. Another TZD, rosiglitazone, is also used in the treatment of type 2 diabetes. Troglitazone has been withdrawn from clinical use, and other TZDs, such as ciglitazone, have not proceeded into clinical use. Pioglitazone, like other TZDs, improves insulin action mainly by activation of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Peroxisome proliferator-activated receptor-gamma is most strongly expressed in adipose tissue and weakly expressed in liver and skeletal muscle, and activation of PPAR-gammain these tissues reinforces the effects of insulin. Pioglitazone may exert effects on other tissues that express PPAR-gamma ..... © 2007

UR - https://www.scopus.com/pages/publications/84883947633

U2 - 10.1016/B978-008055232-3.62424-9

DO - 10.1016/B978-008055232-3.62424-9

M3 - Chapter (peer-reviewed)

SN - 978-0-08-055232-3

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier

ER -

Pioglitazone

Abstract

Access to Document

Other files and links

Fingerprint

Biguanides

Ciglitazone

Metformin

Cite this